# Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia

> **NCT00588809** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 47 (actual)

## Conditions studied

- Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Adult Acute Promyelocytic Leukemia (M3)
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Neoplasms
- Recurrent Adult Acute Myeloid Leukemia
- Secondary Acute Myeloid Leukemia

## Interventions

- **DRUG:** selumetinib

## Key facts

- **NCT ID:** NCT00588809
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2012-04
- **Final completion:** 2012-12
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2015-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00588809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00588809, "Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00588809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*